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(reviewed by Freland and Beaulieu, 2012). This finding poured gas 
onto the GSK-3 fire in neuroscience research. Subsequent multiple 
studies have shown associations between dysregulation of GSK-
3-mediated signaling pathways and the pathogenesis of bipolar 
disorder (reviewed in Jope, 2011), Fragile X syndrome (reviewed 
in Mines and Jope, 2011), schizophrenia (reviewed in Emamian, 
2012), brain tumors (reviewed in Mills et al., 2011), and stroke 
(reviewed in Chuang et al., 2011). Several independent studies have 
also shown the involvement of GSK-3 in the action of the mono-
amine neurotransmitters serotonin and dopamine that are central 
targets for antidepressant and antipsychotic drugs (reviewed in 
Beaulieu et al., 2011; Polter and Li, 2011) therefore suggesting that 
GSK-3 may constitute an important “missing link” between disease 
mechanisms and treatments for mental illnesses.
In 2000, the first mouse knockout model of GSK-3 (beta) was 
reported (reviewed in Kaidanovich-Beilin and Woodgett, 2011), 
and provided the first of many tools for physiological analysis 
of GSK-3’s roles. Subsequent transgenic models of GSK-3 have 
allowed its role to be elucidated in the mechanism of monoamine 
neurotransmitter action (reviewed in Beaulieu et al., 2011; Polter 
and Li, 2011) and synaptic plasticity (reviewed in Bradley et al., 
2012), neurodevelopment (reviewed in Kim and Snider, 2011; Cole, 
2012), neuronal morphogenesis (reviewed in Kim et al., 2011), 
apoptosis, and neuronal survival (reviewed in Gomez-Sintes et al., 
2011) as well as neuroinflammation (reviewed in Beurel, 2011).
Hence a single pair of signaling molecules can be found at the 
center of multiple neuronal functions. Indeed, these roles posi-
tioned GSK-3 as a potential therapeutic target for both psychiatric 
and neurodegenerative diseases and a series of pharmacological 
inhibitors with alternative modes of actions have been generated 
over last two decades (reviewed in Eldar-Finkelman and Martinez, 
2011). We certainly hope that these molecules will prove useful and 
safe in the clinic as there are many unmet needs in both psychiatry 
and dementia-related medicine. That said, study of GSK-3 in the 
brain has uncovered many important facets of brain biology and 
there is clearly much more to be revealed.
Acknowledgments
We thank all of the contributors to this volume from around the 
world (UK, Belgium, Italy, Spain, Israel, Japan, Australia, USA, 
and Canada) for their informative reviews of the many different 
facets of GSK-3 neurobiology. We also appreciate the effort of the 
reviewers for their comprehensive manuscript evaluations and 
suggestions.
I know that I know nothing (Socrates, 469 BC–399 BC)
This Research Topic is dedicated to a rather unique cellular reg-
ulator termed Glycogen Synthase Kinase-3 (GSK-3). In the late 
1970s, this protein serine kinase was first discovered through its 
ability to activate the ATP-Mg-dependent form of type-1 protein 
phosphatase (Factor A activity) and to phosphorylate the key rate-
limiting metabolic enzyme that catalyzes the last step of glyco-
gen synthesis, glycogen synthase. From five chromatographically 
separable glycogen synthase kinases, the third (GSK-3) was sub-
sequently demonstrated to mediate the effect of insulin on activa-
tion of glycogen synthesis: insulin leads to inactivation of GSK-3 
which relieves its inhibitory phosphorylation of glycogen synthase. 
Molecular cloning in 1990 revealed the existence of two distinct 
genes for GSK-3, which encode two paralogous signaling proteins 
termed GSK-3α and GSK-3β (reviewed in Kaidanovich-Beilin 
and Woodgett, 2011). GSK-3 has intrigued many researchers for 
over 30 years by its unusual features, mechanisms of regulation, 
its participation within at least four major signaling systems, and 
its capacity to influence the functions of more than 100 substrates 
(reviewed in Kaidanovich-Beilin and Woodgett, 2011).
While GSK-3 was initially identified as a regulator of metabo-
lism, a significant role in neuroscience has since emerged. The 
first indication of an important brain function was made in 1992 
by Hanger et al. (1992) who showed that GSK-3 phosphorylates 
the microtubule-associated protein tau at sites relevant to the 
pathology of Alzheimer’s disease, further supported by studies 
by Takahashi et al. (1994) who demonstrated that Tau was indeed 
a physiological substrate of GSK-3, which at that time was also 
called tau protein kinase I (TPKI) (reviewed in Kremer et al., 2011; 
Medina et al., 2011; Takashima, 2012). These findings were impor-
tant milestones for initiating interest in GSK-3 in the pathogenesis 
of neurodegenerative disorders, such as Alzheimer’s disease (see 
Gomez-Sintes et al., 2011; Kremer et al., 2011; Medina et al., 2011; 
Takashima, 2012).
In parallel to the aforementioned discoveries, GSK-3 was shown 
to be a major regulator of the Wnt signaling pathway. In 1995, 
studies in Xenopus laevis showed that the expression of a catalyti-
cally inactive mutant of GSK-3 induces duplication of the dorsal 
axis, a phenotype similar to earlier studies of lithium ion treat-
ment of Xenopus embryos. A molecular explanation for this rela-
tionship was discovered in 1996 when GSK-3 was shown to be 
inhibited by lithium (see chapter by Valvezan and Klein, 2012). 
Lithium was a gold standard in the treatment of bipolar disorder 
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